{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n LINC00239 is emerging as an oncogenic long non‐coding RNA implicated in multiple cancer types through distinct mechanisms. In esophageal squamous cell carcinoma (ESCC), LINC00239 is highly expressed and correlates with poor patient prognosis. Functional studies demonstrate that its overexpression enhances cell proliferation, metastasis, invasion, and the epithelial–mesenchymal transition. Mechanistically, LINC00239 directly binds to MBP‑1, thereby attenuating its repression of c‑Myc transcription and promoting oncogenic signaling."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In acute myeloid leukemia (AML), linc00239 is similarly upregulated in patient samples and cell lines, where it drives increased cell viability, colony formation, and migration, while also conferring chemoresistance to doxorubicin. These effects have been linked in part to the activation of the PI3K/Akt/mTOR pathway."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Moreover, differential expression of LINC00239 has been incorporated into prognostic risk scoring systems to predict overall and recurrence‑free survival in hepatocellular carcinoma (HCC) patients. In these studies, altered levels of LINC00239 contribute to the molecular signatures that distinguish patients with different prognoses, thereby underscoring its potential utility as a biomarker."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings indicate that LINC00239 promotes tumor progression via multiple axes—by modulating transcriptional regulation in ESCC, activating survival pathways in AML, and serving as a predictive biomarker in HCC—highlighting its promise as a target for novel antitumor therapies.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Xiaoliang Liang, Juntao Lu, Zheng Wu, et al. "}, {"type": "b", "children": [{"type": "a", "children": [{"type": "t", "text": "i"}], "href": "i"}, {"type": "t", "text": "LINC00239"}, {"type": "a", "children": [{"type": "t", "text": "/i"}], "href": "/i"}, {"type": "t", "text": " Interacts with C-Myc Promoter-Binding Protein-1 (MBP-1) to Promote Expression of C-Myc in Esophageal Squamous Cell Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Cancer Res (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1541-7786.MCR-20-1025"}], "href": "https://doi.org/10.1158/1541-7786.MCR-20-1025"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34016746"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34016746"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Yuting Yang, Wenshu Dai, Yingwei Sun, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Long non‑coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncol Rep (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/or.2019.6991"}], "href": "https://doi.org/10.3892/or.2019.6991"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30720129"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30720129"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Jiaxiang Ye, Haixia Li, Jiazhang Wei, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Risk Scoring System based on lncRNA Expression for Predicting Survival in Hepatocellular Carcinoma with Cirrhosis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Asian Pac J Cancer Prev (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.31557/APJCP.2020.21.6.1787"}], "href": "https://doi.org/10.31557/APJCP.2020.21.6.1787"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32592379"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32592379"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Jiaxiang Ye, Siyao Wu, Shan Pan, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncol Rep (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/or.2020.7528"}], "href": "https://doi.org/10.3892/or.2020.7528"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32323856"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32323856"}]}]}]}